Find Clinical Trials

Introducing TrialConnect™
A new service offered by the American Brain Tumor Association links brain tumor patients with appropriate clinical trials based on the patient's tumor type and treatment history. TrialConnect™, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Call 877-769-4833 or Read more.  A single, short, secure questionnaire matches patients to enrollment criteria for over 100 brain tumor clinical trials. EmergingMed staff then help patients connect to the right trial coordinators.

Explore these sites for information about brain tumor clinical trials (research treatments). Some of these sites offer searchable databases, some focus on a single trial. Each provides contact information for further details.

Cancer.gov or
ClinicalTrials.gov
These two government databases list almost 200 industry, institutional, and government-sponsored brain tumor trials. The databases can be searched by tumor type, treatment type, sponsor type, patient age, or geographic region. Both US and international trials are listed. This information is also available free by phone from the National Cancer Institute's Cancer Information Service. Call 800-422-6237 and choose the option of speaking to a Cancer Information Specialist. The service is available in both English and Spanish. 

*****

Clinical Trials and Noteworthy Treatments for Brain Tumors
This site offers a database of both clinical trials and new, conventional treatments for brain tumor patients. The database can be searched by treatment category, by state, or by tumor type.

*****

Clinical Trials at the National Institutes of Health
The Clinical Center at the National Institutes of Health (NIH) conducts clinical trials - research studies - for many diseases, including brain tumors. There is no charge for medical care received at the NIH Clinical Center. While patients are responsible for travel costs for their initial visit or consultation, once enrolled in a trial at the Center, patients may be able to obtain assistance with transportation as well as per-day funds to help offset food and lodging expenses while at NIH. 
 
The Center has many different brain tumor trials. The majority, but not all, of the trials focus on developing new treatments for recurrent brain tumors. Both adult and pediatric trials are open to enrollment. View a list of the current studies at http://bethesdatrials.cancer.gov/brain_cns/index.asp. Or, you may call the Clinical Center at 1-888-624-1937 to learn more about these studies.  

*****

Coalition of National Cancer Cooperative Groups
CancerTrialsHelp enables visitors to search for clinical trials, register for a monthly electronic newsletter, bookmark favorite sections, and read headlines in cancer news.

*****

Pediatric Brain Tumor Consortium
The Pediatric Brain Tumor Consortium (PBTC) is a multidisciplinary cooperative research organization devoted to the study of correlative tumor biology and new therapies for primary CNS tumors of childhood. Summaries of open PBTC protocols are posted at their website.

*****

Pharmaceutical Research and Manufacturers Of America
PhRMA represents approximately 100 US companies involved in pharmaceutical research. Site includes industry information as well lists of members' new drugs in development.

*****

Specific studies:

Toca 511
A Phase 1/2 Study of Toca 511, a Replication Competent Retrovirus, Administered to Subjects With Recurrent Glioblastoma Multiforme (GBM)

This is a multicenter, open-label, trial of the safety and tolerability of increasing, single doses of Toca 511, a replication competent retrovirus, administered transcranially to subjects with GBM that has recurred following surgery, radiation therapy and chemotherapy with temozolomide. Approximately 3 weeks following injection of Toca 511, subjects will take flucytosine (5-FC), an oral antibiotic, for 6 days.  These 6-day cycles will be repeated monthly for up to 6 cycles.  The study will be conducted in 2 parts.  In part one, increasing, single doses of Toca 511 will be administered to approximately 15 subjects in order to identify the highest safe and tolerated dose of Toca 511.  In part 2, an additional 9 subjects will be studied at the dose found in part one to be safe and well tolerated.  Tumor response will be assessed by MRI scan performed approximately every 2 months.

For more information including entry criteria and study sites, locations, and contact information, please click on the following links or paste the links into your internet browser: http://www.tocagen.com/site/c.quIYL6MOJrE/b.6116599/k.9D00/Clinical_Trials.htm or:
http://clinicaltrials.gov/ct2/show/NCT01156584?term=Tocagen&rank=1


Last updated: December 8, 2011